High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
| Line 8: | Line 8: | ||
| [[CHI-SQUARE Study]] | | [[CHI-SQUARE Study]] | ||
|- | |- | ||
| [[ | | [[A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers]] | ||
|- | |||
| [[Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers]] | |||
|- | |- | ||
| [[CSL-112 Trial - Phase 2a]] | | [[CSL-112 Trial - Phase 2a]] | ||
Revision as of 21:28, 19 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein landmark trials On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
|
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Reconstituted HDL Infusion
CETP Inhibitors
| ACCELERATE Trial |
| DAL-Outcomes Trial |
| DEFINE Trial |
| ILLUMINATE Trial |
| ILLUSTRATE Trial |
| REVEAL Trial |
Niacin
| AIM-HIGH Trial |
| ARBITER 2 Trial |
| ARBITER 3 Trial |
| ARBITER 6-HALTS Trial |
| CLAS Trial |
| HATS Trial |
| Oxford Niaspan Study |
Fibrate
| VA-HIT Trial |
| BECAIT Trial |
| BIP Trial |
Statin
| ASTEROID Trial |
| SATURN Trial |
| 4S Trial |
| CORONA Trial |
Multiple Lipid Lowering Drugs
| HARP Study |
| AFREGS Trial |